Immunotherapy is among the most rapidly evolving treatment strategies in oncology. The
therapeutic potential of immune-checkpoint inhibitors is exemplified by the recent hail of …

Recent Developments in Radiotherapy | NEJM Skip to main content NEJM Group Follow Us
Facebook Twitter Instagram YouTube LinkedIn Prepare to become a physician, build your …

Chimeric antigen receptor (CAR) T cells have demonstrated promising efficacy, particularly
in hematologic malignancies. One challenge regarding CAR T cells in solid tumors is the …

PURPOSE Women have more adverse events (AEs) from chemotherapy than men, but few
studies have investigated sex differences in immune or targeted therapies. We examined …

Aim Chemotherapy side effects are often reported in clinical trials; however, there is little
evidence about their incidence in routine clinical care. The objective of this study was to …

Purpose Evolving treatments, disease phenotypes, and biology, together with a changing
drug development environment, have created the need to revise castration-resistant prostate …

Importance To integrate the patient perspective into adverse event reporting, the National
Cancer Institute developed a patient-reported outcomes version of the Common …

Full integration of oncology and palliative care relies on the specific knowledge and skills of
two modes of care: the tumour-directed approach, the main focus of which is on treating the …

Objective To describe the development and validation of a novel patient reported outcome
measure for symptom burden from long covid, the symptom burden questionnaire for long …

Abstract Purpose Symptomatic adverse events (AEs) are monitored by clinicians as part of
all US-based clinical trials in cancer via the US National Cancer Institute's Common …